Stevens First Principles Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-891	Closed	-$32K	–	174
2016 Q4	$32K	Hold	891	–	–	0.02%	115
2016 Q3	$41K	Buy	+891	New	+$46.5K	0.03%	100
2015 Q4	–	Sell	-1,000	Closed	-$56K	–	203
2015 Q3	$56K	Buy	+1,000	New	+$64.8K	0.04%	115
2015 Q1	–	Sell	-300	Closed	-$17K	–	228
2014 Q4	$17K	Sell	300 -625	-68%	-$34.8K	0.01%	164
2014 Q3	$50K	Hold	925	–	–	0.03%	148
2014 Q2	$48K	Buy	925 +500	+118%	+$25.6K	0.03%	149
2014 Q1	$22K	Sell	425 -15	-3%	-$693	0.01%	160
2013 Q4	$18K	Hold	440	–	–	0.01%	168
2013 Q3	$17K	Sell	440 -120	-21%	-$4.68K	0.01%	165
2013 Q2	$22K	Buy	+560	New	+$21.8K	0.02%	160

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Stevens First Principles Investment Advisors's TEVA Position: Q1 2017 in Review

Stevens First Principles Investment Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 891 shares — an estimated $32K sold.

Stevens First Principles Investment Advisors first reported a position in TEVA in Q2 2013 and held it in 10 quarters. The position peaked at $56K in Q3 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Stevens First Principles Investment Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Stevens First Principles Investment Advisors sold 891 Teva Pharmaceuticals shares in Q1 2017, an estimated $32K.
Stevens First Principles Investment Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Stevens First Principles Investment Advisors's Teva Pharmaceuticals position peaked at $56K in Q3 2015.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Stevens First Principles Investment Advisors's 13F filing for Q1 2017, filed 2 May 2017.